Navigation Links
National Institute of Neurological Disorders and Stroke (NINDS) Stops Enrolling Patients in ARUBA Study Earlier Than Planned
Date:5/10/2013

New York, nY (PRWEB) May 10, 2013

Today the National Institute of Neurological Disorders and Stroke (NINDS) announced that “A Randomized Trial of Unruptured Brain Arteriovenous Malformations” (ARUBA) has stopped enrolling patients because of higher than expected event rates in the interventional therapy arm.

The International Center for Health Outcomes and Innovation Research (InCHOIR) at the Icahn School of Medicine at Mount Sinai is the international data-coordinating center for the trial. “We have discovered that, in an interim analysis of the data collected so far, medical management was superior to interventional therapy for patients with unruptured brain arteriovenous malformations,” said Alan J. Moskowitz, MD, Professor and Vice Chair of Health Evidence and Policy at the Icahn School of Medicine, and Co-Director of InCHOIR). “It is our recommendation that extended follow-up is needed to determine whether these disparities in rates will persist over time.”

The data, analyzed by InCHOIR under the direction of Michael Parides, PhD, Director of the Center for Biostatistics at the Icahn School of Medicine at Mount Sinai, has shown that after a mean follow-up of 33 months, the event rate in the intervention group was more than three times higher than in the medical management group. The analysis included data from 224 participants enrolled in the study’s 39 worldwide sites, in an effort that was coordinated by Ellen Moquete, RN, BSN, Director of Trials Operations at InCHOIR. Originally, the study planned to enroll 400 participants, however, because of the higher than expected event rate in the interventional therapy arm, the ARUBA Data and Safety Monitoring Board has recommended stopping enrollment while continuing to follow those in the study to see if the difference changes over time.

Another key endpoint in the trial is functional status, said Dr. Parides. “Continued follow-up of patients will help determine whether the observed differences in event rates will translate into meaningful long-term differences in patient functioning.”

ARUBA is a randomized, multi-center trial designed to evaluate whether symptomatic medical management improves long-term outcomes of patients with unruptured brain arteriovenous malformations compared to invasive treatment for the composite event of death from any cause or symptomatic stroke. There will be a detailed analysis of the data as well as further results presented at the European Stroke Conference in London on May 31.

The Mount Sinai Medical Center
The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Icahn School of Medicine at Mount Sinai. Established in 1968, the Icahn School of Medicine is one of the leading medical schools in the United States. The Medical School is noted for innovation in education, biomedical research, clinical care delivery, and local and global community service. It has more than 3,400 faculty in 32 departments and 14 research institutes, and ranks among the top 20 medical schools both in National Institutes of Health (NIH) funding and by U.S. News & World Report.

The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation’s oldest, largest and most-respected voluntary hospitals. In 2011, U.S. News & World Report ranked The Mount Sinai Hospital 16th on its elite Honor Roll of the nation’s top hospitals based on reputation, safety, and other patient-care factors. Of the top 20 hospitals in the United States, Mount Sinai is one of 12 integrated academic medical centers whose medical school ranks among the top 20 in NIH funding and U.S. News & World Report and whose hospital is on the U.S. News & World Report Honor Roll. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 560,000 outpatient visits took place.

For more information, visit http://www.mountsinai.org/
Find Mount Sinai on Facebook, Twitter and YouTube.

# # #

Read the full story at http://www.prweb.com/releases/2013/5/prweb10723442.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. MU receives national award for using mind-body approach to improve health
2. International breast health global summit will focus on supportive care and quality of life
3. International conference to explore health of descendants of transatlantic slave trade
4. National poll: Low cost, lifesaving services missing from most older patients health care
5. UT MD Anderson President Ronald DePinho elected to National Academy of Sciences
6. Kessler Foundation researchers present at first International Congress on Cognition in MS
7. Dr. Yael Mosse will receive first Nachman Award in Pediatric Oncology at national conference
8. Georgetown physician leads national resveratrol study for Alzheimers disease
9. National initiative launched to change the way biology departments approach undergraduate education
10. Boston researcher, surgical oncologist receives national award
11. Internationally known expert in ovarian cancer to be honored at the ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
Breaking Medicine Technology: